CommercialCoverageMedium impact
Prostate Artery Embolization for Benign Prostatic Hyperplasia (7.01.55)
Blue Shield of California·CA · Urology, Radiology·Medical Policy
Effective date
Aug 1, 2026
We identified it
Jul 31, 2026
Summary
Blue Shield of California has classified Prostate Artery Embolization (PAE) for benign prostatic hyperplasia as investigational, effective August 1, 2026. This means PAE procedures will not be covered as a standard treatment; claims will be denied unless the member's contract specifically provides coverage for investigational procedures or state law mandates coverage of FDA-approved services. Billing teams must implement prior authorization requirements and set up denial protocols.
Action Required
By July 15, 2026: Billing team must update billing system to flag all PAE-related claims for Prostate Artery Embolization (CPT codes for interventional radiology procedures involving prostate embolization) as requiring prior authorization and documentation review. Implement denial protocols for claims without explicit member contract language allowing investigational procedures. Providers should verify member eligibility for investigational coverage BEFORE scheduling. Update encounter forms and EMR templates to capture medical necessity documentation. Contact Blue Shield of California directly to obtain specific CPT codes used for PAE billing, as the policy references 'Codes table for details' but specific codes are not listed in the provided excerpt. Note: Some state or federal law may require coverage of FDA-approved services—verify member contract language and applicable state regulations before issuing final denials.